Xenon Pharmaceuticals Inc. — Director's Dealing 2021

May 20, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Xenon Pharmaceuticals Inc. (XENE)
CIK: 0001582313
Period of Report: 2021-05-18

Reporting Person: Hayden Michael R (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-05-18	Common Shares	M	3500	$3.85	Acquired	116206	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-05-18	Stock Option (Right to Buy)	$3.85	M	3500	Disposed	2027-05-31	Common Shares (3500)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Shares	92076	Indirect
Common Shares	114403	Indirect

Footnotes

F1: No shares were sold by the Reporting Person in connection with the exercise and the common shares issued as a result of the exercise are subject to the terms of a lock-up agreement executed by the Reporting Person in favor of the underwriters of the Company's public offering in March 2021.

F2: Michael Hayden is the president and principal beneficial shareholder of Genworks Inc.

F3: One-third of the total shares subject to the Option shall vest on the one year anniversary of the grant date, one-third of the total shares subject to the Option shall vest on the two year anniversary of the grant date, and the balance of the total shares subject to the Option shall vest on the three year anniversary of the grant date. The original grant date of the option is June 1, 2017.